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Association with SNPs within SLC22A4 and SLC22A5
Camilla Friberg1, Karin Bjo¨rck2, Staffan Nilsson2, Annica Inerot3, Jan Wahlstro¨m1 and Lena Samuelsson1
We have previously reported a region on chromosome 5q as a possible susceptibility region for psoriasis. This
cytokine cluster-rich region has also been suggested as a susceptibility locus in other autoimmune or
inflammatory diseases including Crohn’s disease (CD) and rheumatoid arthritis (RA). Three specific single-
nucleotide polymorphisms (SNPs) have been reported to associate with RA and CD and to change the
functional activity of two organic cation transporters, solute carrier family 22 member 4/5 (SLC22A4) and
(SLC22A5). In this study, we have analyzed these SNPs for an association with psoriasis. We have also performed
a denser linkage analysis of this region with an additional 31 microsatellite markers. We were not able to detect
any association with any of the three SNPs analyzed. However, our linkage result supports the involvement of
this region in the etiology of psoriasis. We obtained a peak non-parametric linkage value of 3.1 for marker
D5S436 in a subgroup of patients with joint complaints. This result supports the findings in another study
of psoriasis patients originating from Iceland in which the authors obtained a peak logarithm of the odds score
of 2.6 for marker D5S2090, only 2 Mb from D5S436. This suggests a psoriasis susceptibility locus on chromosome
5q32 that is involved in the arthritic phenotype of the disease.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disease that affects
approximately 2–5% of the Caucasian population (Nevitt and
Hutchinson, 1996) and around 0.3% in the Mongoloid
population (Yip, 1984). The most common form, psoriasis
vulgaris, is characterized by red scaly plaque caused by the
abnormal proliferation and differentiation of epidermal
keratinocytes and the infiltration of inflammatory cells, in
particular activated T cells (Barker, 1991). Psoriasis is strongly
associated with an inflammatory form of arthritis called
psoriatic arthritis. It affects between 10 and 40% of all
psoriatic patients (Gladman, 1994). Crohn’s disease (CD) is
another disease with a markedly increased prevalence of
psoriasis (Yates et al., 1982; Lee et al., 1990).
As with other complex diseases, the development of
psoriasis is caused by a combination of both genetic and
environmental factors. The search for a contributing genetic
factor has revealed several regions across the genome with
significant linkage values. The psoriasis susceptibility 1 locus
on chromosome 6p21 is the most consistently replicated of
these. This locus is estimated to account for 30–50% of the
genetic contribution to psoriasis (Trembath et al., 1997). In a
genome scan, our group has previously identified candidate
susceptibility regions on chromosomes 3q21, 3p21–23, 5q31,
and 15q11 (Samuelsson et al., 1999). On chromosome 5q31,
marker D5S816 gave an non-parametric linkage (NPL) value
of 2.22 in the total family material and increased to
NPL¼ 2.45 in a subgroup stratified for joint complaints
(Samuelsson et al., 1999). After application of the information
content term prediction score (Knutsson, 2002) to the whole
genome scan, chromosome 5q was one of the regions that
was a natural target for denser genotyping (Figure 1).
Overlapping genetic locations of loci for different auto-
immune diseases have been known for several years. The
distal region on chromosome 5q has been suggested to
harbor susceptibility loci for autoimmune or inflammatory
diseases such as CD, rheumatoid arthritis (RA), and asthma
(Grunig et al., 1998; Kauppi et al., 2001; Rioux et al., 2001;
Tokuhiro et al., 2003; Peltekova et al., 2004). Three single-
nucleotide polymorphism (SNPs) located in this region have
been reported to alter the functional activity of two organic
cation transporters, solute carrier family 22 member 4/5
(SLC22A4) and (SLC22A5). One of the SNPs (rs3792876) has
been associated with RA (Tokuhiro et al., 2003). The other
two SNPs (rs1050152, rs2631367) form a haplotype, which
has been associated with CD (Peltekova et al., 2004). These
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genes, SLC22A4 and SLC22A5, are located just less than
4 Mb upstream from the microsatellite marker that generated
the peak NPL value on chromosome 5 in our genome-wide
scan (D5S816).
Recently, another report on linkage to this region was
presented. Karason et al. (2005) obtained a logarithm of the
odds score of 2.6 for marker D5S2090 in a scan of female
psoriasis patients. This marker maps within 17 Mb of
rs3792876 associated with RA and 12 Mb from marker
D5S816.
Taken together, there are several reasons why we believe
further investigation of the 5q region is of great importance in
psoriasis. They are the results of our genome-wide scan, the
logarithm of the odds score of psoriasis patients originating
from Iceland, and the association of this region with other
inflammatory diseases. Additionally, this region harbors a
cytokine gene cluster and other immunologically active
genes that are good candidate genes for psoriasis.
The aim of this study was therefore to refine the linkage
analysis in this region with a denser set of microsatellite
markers. In addition, we wanted to perform an association




When calculating the prediction scores of our genome scan,
the maximum predicted NPL value was 3.9 on chromosome
5q (Figure 1). This was one of the highest predicted NPL
values in the entire genome scan. Linkage analysis was
performed on a total of 114 multiaffected families for 34
markers within this region. The families were further stratified
into two groups, one group of 55 families with joint
complaints and one group of 59 families without joint
complaints. The result of the unstratified family set gave a
maximum NPL value of 1.6 for marker D5S436, whereas in
the subgroup with joint complaints, the NPL value reached
3.1 (P¼0.001) for the same marker (Figure 2). Of individual
families in the group with joint complaints, 59% had an NPL
value 40 and 40% had an NPL value 41. The 95%
confidence interval for the peak position in the subgroup
spanned between marker rs1050152 and D5S2112. In the
subgroup without joint complaints, there were no NPL values
above 1 (Figure 2). The difference in NPL value at marker
D5S436 between the two subgroups was significant
(P¼0.003).
We have also performed an NPL analysis only including
affected females. In contrast to Karason et al., we did not
observe an increase in the NPL value (data not shown).
Stratification in our previous genome scan generated an
NPL score of 2.64 at marker D3S1551, located at psoriasis
susceptibility 5 on chromosome 3q21, for the subgroup with
joint complaint (Samuelsson et al., 1999). In order to
investigate correlation between these loci, we calculated
the family-wise NPL-values at D5S436 and D3S1551 in the
joint complaint set.
There was a slight degree of negative correlation
(r¼0.315, P¼0.037).
Association analysis
The SNPs, rs3792876, rs1050152, and rs2631367, were all
analyzed separately, as well as in haplotypes of two to three
markers per haplotype. The analysis was performed on both
the total family material of 264 families and on the subgroup
of 102 families with joint complaints. Neither analysis
produced any significant association results.
Power calculations
The smallest detectable attributable fraction, that is, the
proportion of cases caused by a particular exposure, and the
corresponding odds ratio (OR) required for a power of 80%
under four genetic models are shown in Table 1. Under most
models, an OR of approximately 2 would be sufficient for all
SNPs.
DISCUSSION
In a typical genome-wide scan of a genetically complex
disease such as psoriasis, several genomic regions suggestive
of a susceptibility locus are usually identified. To start
confirmational studies of all candidate regions at the same
time is both time and resource consuming, since not all of











Figure 1. NPL values and prediction score values from our genome scan














Figure 2. Result of linkage analysis of chromosome region 5q31–32. (a) Total
family material (114 families), (b) families with joint complaints (55 families),
and (c) families without joint complaints (59 families).
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to choose the peak regions with which to begin. If we rely
solely on the peaks to determine continued research,
interesting regions may be overlooked if information is
incomplete owing to low heterozygosity, failed genotyping,
or low marker density. A low score can therefore be owing to
poor information, rather than the absence of linkage. Current
measures of information, such as information content graphs,
have the disadvantage of not combining the informativeness
with the obtained score. A more desirable approach is to
extrapolate the outcome of incomplete data on the basis of
the observed data, to be able to compare the levels of
information in a linkage context. This is the simple yet
appealing idea of prediction scores. When we applied this
evaluation tool to data from our genome scan, the chromo-
some region 5q31–32 was indicated as having low NPL
values owing to low information content.
We therefore decided to perform a denser linkage analysis
on chromosome 5q31–32. By slightly increasing the family
material and analyzing a denser set of microsatellite markers,
we obtained an increase in the NPL score from 2.45 to 3.1 in
the subgroup with joint complaints. This NPL value is not
surprising considering the size of the family material and the
fact that this is probably a minor psoriasis locus compared
with the major histocompatability complex region (psoriasis
susceptibility 1). The peak NPL score of the joint complaint
subgroup together with the significant difference in NPL
value between the two subgroups indicate an arthritic
involvement of the region around the peak marker D5S436
in psoriasis patients. In the total family material, the NPL
value decreased from 2.22 to about 1.6. This emphasizes the
importance of stratifying patients according to phenotypic
criteria, which has also been underlined recently by Karason
et al. (2005).
The psoriasis susceptibility 5 locus on chromosome 3q21
also associates with joint complaint. In order to investigate a
possible epistasis or locus heterogeneity between these two
loci, we calculated the family-wise NPL values at D5S436
and D3S1551 in the joint complaint set. We found a negative
correlation between the NPL values indicating possible locus
heterogeneity for the two loci.
Interestingly, marker D5S436 is only 2 Mb from marker
D5S2090, which yielded an logarithm of the odds score of
2.6 in a scan of female psoriasis patients originating from
Iceland (Karason et al., 2005). D5S436 also lies within 5 Mb
from the highest linkage score in the pooled analysis of
European celiac disease families (Babron et al., 2003) and
13.5 Mb from the SNPs that associate with CD or RA. This
genetic overlapping of all these autoimmune/inflammatory
diseases indicates that this cytokine gene-rich 5q region
might harbor a gene involved in a common pathway leading
to autoimmunity.
In this study, we have also analyzed two SNPs within the
gene SLC22A4 and one SNP in the promoter of the gene
SLC22A5, which were previously described by Tokuhiro
et al. (2003) and Peltekova et al. (2004). The frequency of the
SNP that gave significant association under a recessive model
on patients with RA originating from Japan is, however,
considerably lower in the Caucasian population (0.09 vs 0.33
and 0.008 vs 0.11 for homozygotes). Hence, an OR of 15.4
(Table 1) would be required for the association to be
detectable in our study using a recessive model. Assuming
the OR in Tokuhiro et al. (OR¼ 1.98) power is lacking in our
material. However, considering the low allele frequency, we
regard it unlikely that this would be a disease-involved
polymorphism in a complex genetic disease such as psoriasis.
Our data was also compared with the study on patients
with CD (Peltekova et al., 2004). When applying the OR of
rs1050152 and rs2631367 presented by Peltekova et al. (OR
2.56 for heterozygotes), the power of our material is larger
than or equal to 97% for both SNPs under additive and
multiplicative models. These models seem to be the likely
models considering the reported OR (OR 2.56 for hetero-
zygotes, OR 5.14 for homozygotes).
Needless to say, this does not totally exclude the genes
SLC22A4 and SLC22A5 from involvement with psoriasis.
However, our lack of association to rs3792876, rs1050152,
and rs2631367 is in line with another study performed on
psoriatic arthritis patients (Butt et al., 2005) and with two
studies performed on Canadian Caucasian RA patients
(Newman et al., 2005) and RA patients originating from the
United Kingdom (Barton et al., 2005).
To summarize, our results support a susceptibility region
for psoriasis on chromosome 5q32, probably involved in the
arthritic phenotype of the disease. Our data also indicate that
the three functional SNPs that associate with RA or CD are
not involved in psoriasis susceptibility in our population.
MATERIALS AND METHODS
Study population
Ascertainment of families were through membership register of the
Swedish psoriasis association (Inerot et al., 2005). For the linkage
analysis, we used 114 nuclear families with unaffected parents
available for genotyping and at least two affected children (481
individuals, 168 affected sib pairs). Of these, 86 families (366
individuals, 134 affected sib pairs) had previously been analyzed in
Table 1. Attributable fraction (AF) and corresponding
odds ratio (OR) required for a power of 80%
Additive Multiplicative Recessive Dominant
rs3792876
AF 0.15 0.14 0.06 0.15
OR 2.21 2.01 15.4 2.2
rs1050152
AF 0.41 0.36 0.20 0.57
OR 1.81 1.61 2.3 3.0
rs2631367
AF 0.45 0.40 0.22 0.65
OR 1.91 1.61 2.3 3.6
1Odds ratio for heterozygotes.
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our genome scan. In order to confirm our previous findings for this
locus, we divided the families based on joint complaints in affected
individuals (giving 55 families in this group compared to 44 in the
genome scan) or not (59 families compared to 42 in the genome
scan). The association analysis was complemented with an
additional set of 152 trios. Of these, 47 had and 52 did not have
joint complaints as defined previously. For 53 simplex families, the
status was unclear and hence was not used in the stratified analysis.
In all, we used 264 families, of which 102 had joint complaints. The
stratification criteria for joint complaint were based on self-reporting
by probands in simplex families. Participating individuals in multi-
plex families was examined for joint involvement by one dermato-
logist. More detailed information about the ascertainment of families
and stratification criteria is available elsewhere (Samuelsson et al.,
1999; Inerot et al., 2005). The collection of all samples was made
with informed consent and was approved by the local ethics review
committee and all the studies were performed in accordance with
the requirements of the Declaration of Helsinki Principles.
Prediction scores
Prediction scores (Knutsson, 2002) make predictions for partially
uninformative affected sib-pair families by extrapolating the out-
come of incomplete data on the basis of observed data; in other
words, re-calculating scores conditioned on the existing data. In
regions where the degree of information is low, but available data
provide some support for linkage, the scores increase considerably.
The prediction scores are not affected in regions with complete
information and can never be smaller than the corresponding NPL
score. Note that the prediction score should not be regarded as a test
statistic but as a guideline for identifying regions worth the effort of
further genotyping to increase information. The calculations are
performed in a script utilizing ibd-sharing probabilities generated by
Genehunter v.2.1 (Kruglyak et al., 1996).
Markers and genotyping
A total of 31 microsatellite markers and three SNPs were analyzed
(Table S1). The markers are spaced over a region of 37.4 Mb around
the peak marker from the genome scan, D5S816 (Samuelsson et al.,
1999). Polymerase chain reactions were performed in a total volume
of 10ml, containing 25 ng of genomic DNA, 7.5 pmol of each primer,
and 1 AmpliTaq Golds PCR Master Mix (Applied Biosystems,
Foster City, CA). Polymerase chain reaction amplifications were
carried out on a Gene Amps PCR System 9700 (Applied Biosystems)
with an annealing temperature of 551C, or with a touch-down
interval between 60 and 501C. Genotyping was performed on an
ABI3730 using GeneMapper software (Applied Biosystems).
Genotyping of the three SNPs was performed with either Taqman
SNP Genotyping Assays or Custom Taqman SNP Genotyping Assays
from Applied Biosystems. All Taqman reactions were prepared
according to the manufacturer’s instructions and detection was
performed on an ABI7900HT sequence detection system instrument
(Applied Biosystems).
Statistical analysis
Linkage analysis was performed with Allegro v.1.2c (Gudbjartsson
et al., 2000). Association analysis was calculated using the family-
based association test (Rabinowitz and Laird, 2000; Horvath et al.,
2004). Confidence interval for the position of an NPL score was
determined by bootstrap sampling. The difference in NPL score
between two groups was assessed by a permutation test. Correlation
between NPL values was used to test for possible epistasis or locus
heterogeneity between two loci. In addition, linkage analysis was
carried out on female patients only.
Power calculation
The power of the family-based association test statistic was assessed
with PBAT 3.0 (Lange et al., 2004; Steen and Lange, 2005) using
simulation. Pedigree structure, number of missing founder geno-
types, and founder allele frequencies identical to the observed data
set were used, along with a population prevalence of 3%. Power was
computed under four inheritance models: additive, multiplicative,
recessive and dominant, and the least detectable attributable
fraction, respectively OR at 80% power was reported. A type I error
rate of 0.05 was used in all calculations.
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